Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Treated with DSP-5423P Using PET.

Dopamine D2 Receptor Occupancy in Patients with Schizophrenia Treated with DSP-5423P Using PET. (Phase 2)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221869

Enrollment

Registered

2012-07-27

Start date

2012-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : DSP-5423P INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients who have a diagnosis of schizophrenia as defined by DSM-IV-TR - 20 years old or more and under 64 years old or less, etc.

Exclusion criteria

Exclusion criteria: - Patients who fall under a contraindication listed in the LONASEN package insert - Patients with Parkinson disease, etc.

Design outcomes

Primary

Measure	Time frame
striatal dopamine receptor occupancy the striatal dopamine receptor occupancy after administration of DSP-5423P for 2 weeks.	—

Secondary

Measure	Time frame
PANSS total score and CGI score Change after administration of DSP-5423P for 2 weeks in PANSS total score and CGI score	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026